Plain-English translation of NCT07642362 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Myeloma research guide →This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This study is testing a personalized digital platform designed to help patients with multiple myeloma better manage their condition and improve their overall quality of life. You would use the platform to report your symptoms and side effects, and depending on which group you're in, you may receive personalized educational materials and supportive content to help you cope with your treatment. Your regular medical care continues as normal throughout the study.
Many patients with multiple myeloma struggle with managing side effects and maintaining quality of life during treatment. This study is investigating whether providing personalized educational support through a digital platform can help patients better understand and manage their symptoms, ultimately improving their wellbeing.
You likely qualify if…
You likely don't qualify if…
You would use a personalized digital platform to record your symptoms and side effects. Depending on which group you're randomly assigned to, you'll either receive personalized educational and supportive messages in response to what you report, or simply an acknowledgement that your information was received. Your standard cancer treatment and medical monitoring by your doctor remain completely unchanged throughout the study.
AI-generated summary from trial data · Jun 13, 2026 · Not medical advice
Greece
Sponsor
CareAcross
Collaborators
Μedical Association for the Study of Cancer Biology and Treatments (Μ.Α.S.CA.B.T.)
Enrollment target
~108 participants
Started
February 2025
Primary completion
March 2028
Last updated on clinicaltrials.gov in June 2026.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.